Trial Profile
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-Positive Lymphoid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Rituximab (Primary)
- Indications Lymphoproliferative disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 17 May 2023 Planned End Date changed from 2 May 2023 to 3 May 2024.
- 17 May 2023 Planned primary completion date changed from 2 May 2023 to 3 May 2024.
- 03 Jun 2022 Planned End Date changed from 4 May 2022 to 2 May 2023.